EN DE
Watch HYPHENS PHARMA INTL LIMITED for free: we tell you when fair value or trend changes.
Data-driven stock valuation

HYPHENS PHARMA INTL LIMITED (1J5) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of HYPHENS PHARMA INTL LIMITED stock S$0.40, price S$0.35, upside +14.3%, quality 73 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SG

HP HYPHENS PHARMA INTL LIMITED logo Thin data Nov 15, 2026

HYPHENS PHARMA INTL LIMITED

1J5 · SG

Solid company and rising price, but only slightly cheap (13% below fair value): meets 2 of 3 rules.

Get notified free when this changes
Fair value 0.4000 SGD · Undervalued 
Quality 73/100 
Rising price (uptrend) 
Low debt 
Generates free cash flow 
4.3% dividend yield · Well covered
Ranks above peers (12/15) 
Mixed Growth (revenue 5y +7.5 %/yr in SGD) 
Thin margins · 4.8% net margin (TTM) 
Changed on Nov 9: S$0.7300 → S$0.4000 
Narrow moat 44/100 · thin data
Thin data 
⚠ Small free float
Watch HYPHENS PHARMA INTL LIMITED for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

0.3750 SGD 0.2057 SGD Fair Value 0.4000 SGD Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range 0.2057 SGD – 0.3750 SGD · fair‑value band 0.3000 SGD – 0.5000 SGD · the 0.3500 SGD price screens below the 0.4000 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow HYPHENS PHARMA INTL in your weekly email

Every Wednesday you see whether HYPHENS PHARMA INTL is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally.

Show moreShow less

It operates through Pharmaceutical and Medical Aesthetics; Proprietary Brands; and Digital Platform and E-Pharmacy segments.

The Pharmaceutical and Medical Aesthetics segment markets and sells a range of pharmaceutical and medical aesthetics products, including the Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Piascledine products in ASEAN countries.

This segment focuses on various therapeutic areas, such as dermatology, pediatrics and neonatology, allergy, otorhinolaryngology, orthopedics and rheumatology, radiology, cardiology and interventional cardiology, ophthalmology, gastroenterology, psychiatry, family medicine, and medical aesthetics.

Its Proprietary Brands segment develops, markets, and sells dermatological products comprising Ceradan, TDF, and CG210; health supplements under the Ocean Health brand covering areas, such as heart, joint, physical, cognitive, eye, and health; and pharmaceuticals.

The Digital Platform and E-Pharmacy segment operates a digital platform that services procurement needs of healthcare professionals, healthcare institutions, and retail pharmacies primarily in Singapore.

The company was formerly known as Hyphens Pharma International Pte Ltd and changed its name to Hyphens Pharma International Limited in May 2018. Hyphens Pharma International Limited was founded in 1998 and is headquartered in Singapore.

Stock analysis

HYPHENS PHARMA INTL LIMITED (1J5) currently trades at 0.3500 SGD, while our model-based Fair Value estimate is 0.4000 SGD, implying the stock looks roughly 13% undervalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of 0.8100 SGD per share, and 17 of the 26 models we run sit above the 0.3500 SGD price.

Bear case: the Asset-Based group reads lowest at 0.1400 SGD, and 9 of the 26 models stay below the price. Data coverage for this calculation is low.

Scenario range: 0.3000 SGD (bear) to 0.5000 SGD (bull), the price of 0.3500 SGD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 73/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

HYPHENS PHARMA INTL LIMITED reported revenue of 177M SGD in FY2025 versus 126M SGD in FY2021, a compound +8.9%/yr. Reported net income was 5.8M SGD in FY2025, compounding −3.9%/yr from FY2021.

Key figures

Market cap 108M SGD (≈ $83.9M) Micro · P/E ratio 11.7 · P/S ratio 0.62 · EPS (TTM) 0.0300 SGD · Dividend yield 4.3% · Net margin 4.8% · Return on equity 13.0% · Return on assets (EBIT) 11.1% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 44 out of 100 (low confidence).

What moves the price

The share trades about 7% below its 52-week high and 22% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 38% fair-value upside, at 14%, 1J5 screens richer than that median.

Fair Value models

Bear 0.3000 SGD Fair Value 0.4000 SGD Bull 0.5000 SGD
Price 0.3500 SGD · Upside +14.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 11 months old). Earnings retained since then (0.0132 SGD per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 0.6200 SGD 0.8500 SGD 1.15 SGD 81
Growth DCF 0.6200 SGD 0.8200 SGD 1.07 SGD 80
Owner Earnings 0.4400 SGD 0.6000 SGD 0.8100 SGD 77
All 26 models by family
DCF Models
FCF DCF 0.6200 SGD 0.8500 SGD 1.15 SGD 81
Owner Earnings 0.4400 SGD 0.6000 SGD 0.8100 SGD 77
5Y Revenue Exit 0.5500 SGD 0.8000 SGD 1.10 SGD 73
5Y EBITDA Exit 0.6000 SGD 0.8800 SGD 1.21 SGD 75
5Y P/E Exit 0.4500 SGD 0.6100 SGD 0.7700 SGD 72
10Y Revenue Exit 0.5600 SGD 0.7800 SGD 1.05 SGD 67
10Y EBITDA Exit 0.6000 SGD 0.8300 SGD 1.13 SGD 69
10Y P/E Exit 0.5200 SGD 0.6600 SGD 0.8200 SGD 65
Earnings-Based
Graham-Dodd 0.1300 SGD 0.3800 SGD 0.5100 SGD 65
Lynch FV 0.1600 SGD 0.2400 SGD 0.3100 SGD 61
PEG = 1.0 0.1600 SGD 0.2400 SGD 0.3100 SGD 57
EPV 0.4100 SGD 0.4500 SGD 0.4900 SGD 74
Dividend Discount
Gordon GGM 0.1200 SGD 0.2100 SGD 0.2900 SGD 68
DDM Multi-Stage 0.1200 SGD 0.1800 SGD 0.2300 SGD 67
Multiples
P/E Multiple 0.3000 SGD 0.4000 SGD 0.5000 SGD 63
P/S Multiple 0.2400 SGD 0.3200 SGD 0.4000 SGD 58
P/B Multiple 0.2500 SGD 0.3400 SGD 0.4200 SGD 55
EV/EBIT 0.7200 SGD 0.9300 SGD 1.15 SGD 66
EV/EBITDA 0.6600 SGD 0.8500 SGD 1.04 SGD 67
EV/Revenue 0.5400 SGD 0.7300 SGD 0.9300 SGD 54
Asset-Based
NCAV (Graham) 0.0900 SGD 0.1400 SGD 0.1700 SGD 55
Growth DCF
Growth DCF 0.6200 SGD 0.8200 SGD 1.07 SGD 80
Rev-Margin DCF 0.5500 SGD 0.8000 SGD 1.09 SGD 73
Economic Profit
Residual Income 0.1800 SGD 0.1900 SGD 0.2100 SGD 76
ROIC Compounder 0.4200 SGD 0.4900 SGD 0.5600 SGD 72
Growth Earnings
Growth-Adj P/E 0.2400 SGD 0.3500 SGD 0.4500 SGD 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 73/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 61
How much profit the company makes from its sales and capital
Quality Growth 40
Are margins and returns getting better?
Cashflow 73
Do the profits arrive as real cash?
Financial strength 90
Debt, balance sheet and risk of trouble
Investment 95
Does it invest with discipline instead of growing at any price?
Low Volatility 89
How calm the share price moves, does not count
Price momentum 43
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 53
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 74/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−9.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.5%
Start year 2020 (pandemic). Over 10 years: +8.5% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.5%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
+16.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+11.9%
Dividend (yield on the price)4.3%
Profit margin 2019 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 8%

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−12.6%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Singapore: IMF forecast 2.0% a year to 2030, 1.7% from 2016 to 2025) that is about −14.4% a year for the price.

Watch 1J5, get fair value alerts →

Compare HYPHENS PHARMA INTL LIMITED with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 81 stocks

Beats the industry median on 12/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 73 · Top 25%
Fair Value upside +12.7% · Above median
Profitability
Return on equity (12 months) 13.0% · Top 25%
Return on assets 4.7% · Top 25%
Net margin (12 months) 4.8% · Top 25%
Operating margin (12 months) 7.9% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −0.5% · Below median
Dividend yield (12 months) 4.3% · Above median
Balance sheet
Debt / equity 0.04× · Below median

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/E (12 months) 11.7× · Cheaper than median
P/B 1.57× · Pricier than median
P/S (12 months) 0.62× · Pricier than median
Price / free cash flow (fiscal year) 6.3× · Cheapest 25%
EV/EBITDA 5.4× · Cheaper than median
PEG 0.90× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)50 · sector 34
FUTURE (revenue growth)0 · sector 19
PAST (return on equity)52 · sector 25
HEALTH (low debt)98 · sector 96
DIVIDEND (yield)85 · sector 54

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Sinopharm Group 1099 HK$16.67 HK$50.01 +200% vs 1J5
Jointown Pharmaceutical Group 600998 ¥5.09 ¥11.56 +127% vs 1J5
Shanghai Pharmaceuticals Holding 601607 ¥16.13 ¥35.78 +122% vs 1J5
China National Medicines Corporation 600511 ¥28.38 ¥58.47 +106% vs 1J5
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥19.35 ¥26.64 +38% vs 1J5
Cencora, Inc COR $359.03 $341.58 −5% vs 1J5
Henry Schein, Inc HSIC $86.22 $78.69 −9% vs 1J5
McKesson Corporation MCK $1,103 $822.74 −25% vs 1J5
Galenica AG GALE CHF 91.20 CHF 61.79 −32% vs 1J5
Cardinal Health, Inc CAH $281.10 $163.14 −42% vs 1J5

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

HYPHENS PHARMA INTL LIMITED: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "HYPHENS PHARMA INTL LIMITED Fair Value". https://www.fairvalue-calculator.com/stock/1J5

Frequently asked questions

Is HYPHENS PHARMA INTL LIMITED (1J5) overvalued or undervalued?
As of Nov 15, 2026, our model estimates a fair value of 0.4000 SGD versus a price of 0.3500 SGD, about +14% upside (undervalued).
What is the fair value of 1J5?
Our model-based fair value for HYPHENS PHARMA INTL LIMITED is 0.4000 SGD (as of Nov 15, 2026), built from audited fundamentals. The current price: 0.3500 SGD.
What is the quality score of 1J5?
HYPHENS PHARMA INTL LIMITED has a Quality Score of 73/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for HYPHENS PHARMA INTL LIMITED (1J5)?
Our model-based price target is the fair value of 0.4000 SGD (as of Nov 15, 2026) from 26 valuation models. Cautious scenario 0.3000 SGD, optimistic scenario 0.5000 SGD. It is a calculation from audited fundamentals, not an analyst target.
What is the HYPHENS PHARMA INTL LIMITED stock forecast for 2026?
Our models put fair value at 0.4000 SGD, about +14% upside versus a price of 0.3500 SGD (undervalued). Cautious scenario 0.3000 SGD, optimistic scenario 0.5000 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of HYPHENS PHARMA INTL LIMITED (1J5)?
HYPHENS PHARMA INTL LIMITED reported trailing-twelve-month revenue of about 177M SGD (latest available figure, as of Nov 15, 2026).
Does HYPHENS PHARMA INTL LIMITED pay a dividend?
HYPHENS PHARMA INTL LIMITED currently shows a dividend yield of 4.29% relative to its recent price (as of Nov 15, 2026).
How much is the dividend of HYPHENS PHARMA INTL LIMITED (1J5) and when is the ex-dividend date?
HYPHENS PHARMA INTL LIMITED pays a dividend of 0.015 SGD per share a year, a dividend yield of 4.3%. The last ex-dividend date was May 6, 2026. A dividend has been paid every year since at least 2019. The payout ratio is 50.0% of earnings. Free cash flow covers the dividend 3.77 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into HYPHENS PHARMA INTL LIMITED (1J5)?
Today's price is already fair in a discounted-cash-flow model if free cash flow at HYPHENS PHARMA INTL LIMITED shrinks by 12.6 % per year for five years (discount rate 11.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 7.5 % per year. As of Nov 15, 2026.
What discount rate (WACC) does the fair value of 1J5 use?
Our models discount HYPHENS PHARMA INTL LIMITED at 11.0 %: a base by market capitalisation (micro), damped by beta 0.22, country premium for Singapore. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For HYPHENS PHARMA INTL LIMITED that is -12.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.0 %) and the same formula as our fair value.
How much growth has HYPHENS PHARMA INTL LIMITED (1J5) delivered so far?
Over the past 5 years revenue at HYPHENS PHARMA INTL LIMITED grew 7.5 % a year. The price currently implies free-cash-flow growth of -12.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of HYPHENS PHARMA INTL LIMITED (1J5) growing?
The median revenue growth in the sector is +4.0 % a year. That is the yardstick for the growth priced into HYPHENS PHARMA INTL LIMITED (-12.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of HYPHENS PHARMA INTL LIMITED (1J5)?
The free-cash-flow yield on the price is 16.18 %: that much free cash flow HYPHENS PHARMA INTL LIMITED produces per unit of market value. When it exceeds the discount rate of our models (11.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of HYPHENS PHARMA INTL LIMITED (1J5)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For HYPHENS PHARMA INTL LIMITED it is 0.4000 SGD per share (as of Nov 15, 2026), against a price of 0.3500 SGD. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is HYPHENS PHARMA INTL LIMITED stock overvalued or undervalued in 2026?
As of Nov 15, 2026, 1J5 trades below its calculated fair value: price 0.3500 SGD, fair value 0.4000 SGD, a gap of about +14% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1J5?
No. The price is what the market pays today (0.3500 SGD); the fair value is what the company's own numbers justify (0.4000 SGD). For HYPHENS PHARMA INTL LIMITED the two are 0.0500 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is HYPHENS PHARMA INTL LIMITED worth?
The market values HYPHENS PHARMA INTL LIMITED at about 108M SGD (market capitalisation, as of Nov 15, 2026). Per share that is 0.3500 SGD; our models calculate a fair value of 0.4000 SGD per share.
What do the bullish and bearish scenarios say about 1J5?
Our models span a range for HYPHENS PHARMA INTL LIMITED: cautious scenario 0.3000 SGD, base 0.4000 SGD, optimistic 0.5000 SGD per share (as of Nov 15, 2026, price 0.3500 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1J5?
HYPHENS PHARMA INTL LIMITED trades at a price-to-earnings ratio of 11.7 (as of Nov 15, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 0.4000 SGD is built from several models across several years. Other multiples: PEG 0.9, P/B 1.6, P/S 0.6, EV/EBITDA 5.4.
What is the PEG ratio of 1J5?
The PEG ratio of HYPHENS PHARMA INTL LIMITED is 0.90 (P/E divided by earnings growth, as of Nov 15, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of HYPHENS PHARMA INTL LIMITED (1J5)?
Balance-sheet figures for HYPHENS PHARMA INTL LIMITED (as of Nov 15, 2026): return on equity 13.0%, debt of 0.04 per unit of equity. They feed the Quality Score of 73/100, which measures business quality independently of the share price.
How far is 1J5 from its 52-week high?
HYPHENS PHARMA INTL LIMITED trades at 0.3500 SGD, about 7% below its 52-week high of 0.3750 SGD and 22% above the low of 0.2873 SGD (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of 0.4000 SGD is for.
Which stocks are comparable to HYPHENS PHARMA INTL LIMITED?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is HYPHENS PHARMA INTL LIMITED stock attractive at the current price?
The data as of Nov 15, 2026: price 0.3500 SGD, calculated fair value 0.4000 SGD (+14%), Quality Score 73/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1J5 calculated?
We run HYPHENS PHARMA INTL LIMITED through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 0.4000 SGD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. HYPHENS PHARMA INTL LIMITED currently trades 13% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of HYPHENS PHARMA INTL LIMITED (1J5)?
The closing price on Nov 16, 2026 was 0.3500 SGD. Our model-based fair value is 0.4000 SGD, about +14% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with HYPHENS PHARMA INTL LIMITED right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of HYPHENS PHARMA INTL LIMITED

How large is the market capitalisation of HYPHENS PHARMA INTL LIMITED (1J5)?
The market capitalisation of HYPHENS PHARMA INTL LIMITED is 108M SGD (≈ $83.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of HYPHENS PHARMA INTL LIMITED (1J5)?
The price-to-sales ratio of HYPHENS PHARMA INTL LIMITED is 0.62 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of HYPHENS PHARMA INTL LIMITED (1J5)?
Earnings per share at HYPHENS PHARMA INTL LIMITED are 0.0300 SGD (price ÷ EPS = P/E 11.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of HYPHENS PHARMA INTL LIMITED (1J5)?
The dividend yield of HYPHENS PHARMA INTL LIMITED is 4.3% (payout 50.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of HYPHENS PHARMA INTL LIMITED (1J5)?
The net margin of HYPHENS PHARMA INTL LIMITED is 4.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of HYPHENS PHARMA INTL LIMITED (1J5)?
The return on equity (ROE) of HYPHENS PHARMA INTL LIMITED is 13.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of HYPHENS PHARMA INTL LIMITED (1J5)?
On an EBIT basis the return on assets of HYPHENS PHARMA INTL LIMITED is 11.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of HYPHENS PHARMA INTL LIMITED (1J5)?
The operating margin of HYPHENS PHARMA INTL LIMITED is 7.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at HYPHENS PHARMA INTL LIMITED (1J5)?
Revenue at HYPHENS PHARMA INTL LIMITED is down 0.5% versus a year earlier (3y avg +3.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at HYPHENS PHARMA INTL LIMITED (1J5)?
Earnings per share at HYPHENS PHARMA INTL LIMITED are growing 166% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch HYPHENS PHARMA INTL LIMITED in the live analysis

One click puts HYPHENS PHARMA INTL LIMITED on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.